A degrader targeting pan-KRAS protein and its uses

TW202641562APending Publication Date: 2026-10-16BETTA PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115100552
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-12-30
Filing Date
2026-01-07
Publication Date
2026-10-16

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical technology, specifically relating to a compound targeting KRAS protein degraders and its uses. This invention provides a compound having an FLM structure, or its tautomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein F is a KRAS protein binding fragment; L is a linker unit connecting F and M; and M is a VHL binding fragment. The compound of this invention can be used to treat diseases caused by KRAS mutations or amplifications.
Need to check novelty before this filing date? Find Prior Art